Hematologic Malignancies Clinical Trials in Chapel Hill, North Carolina

5 studies are recruiting for hematologic malignancies in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill, North Carolina

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

   SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory l…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina

   Locations

   32 in total

   Run by

   Sellas Life Sciences Group

   See if you can join NCT04588922 on ClinicalTrials.gov

3. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

   The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06296368 on ClinicalTrials.gov

4. PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

   The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Cancer, Chapel Hill, North Carolina

   Locations

   12 in total

   Run by

   Pulmotect, Inc.

   See if you can join NCT06665100 on ClinicalTrials.gov

5. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov